Panmure Gordon restated their buy rating on shares of Consort Medical plc (LON:CSRT) in a research report sent to investors on Thursday. They currently have a GBX 1,145 ($14.29) price target on the stock.
A number of other research firms have also commented on CSRT. N+1 Singer upgraded Consort Medical plc to a buy rating and raised their price objective for the stock from GBX 1,067 ($13.32) to GBX 1,125 ($14.04) in a research note on Monday, December 19th. Canaccord Genuity restated a buy rating and set a GBX 1,300 ($16.22) price objective on shares of Consort Medical plc in a research note on Thursday, December 1st. Shore Capital restated a buy rating on shares of Consort Medical plc in a research note on Monday. Finally, Investec restated a buy rating and set a GBX 1,170 ($14.60) price objective on shares of Consort Medical plc in a research note on Tuesday, December 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of GBX 1,181.67 ($14.75).
Consort Medical plc (LON:CSRT) traded down 0.55% during midday trading on Thursday, hitting GBX 994.50. The stock had a trading volume of 45,141 shares. The company’s 50-day moving average price is GBX 1,026.23 and its 200 day moving average price is GBX 1,058.77. The company’s market capitalization is GBX 485.84 million. Consort Medical plc has a 52 week low of GBX 935.00 and a 52 week high of GBX 1,180.00.
The firm also recently announced a dividend, which will be paid on Friday, February 17th. Shareholders of record on Thursday, January 19th will be issued a GBX 7.09 ($0.09) dividend. This represents a dividend yield of 0.69%. The ex-dividend date is Thursday, January 19th.
Consort Medical plc Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.